On October 19, 2022, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended the use of either a dose of 20-valent pneumococcal conjugate vaccine (PCV20) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) as previously recommended for adults who have received 13-valent pneumococca...
Kobayashi, Miwako;
Pilishvili, Tamara;
Farrar, Jennifer L;
Leidner, Andrew J;
Gierke, Ryan;
Prasad, Namrata;
Moro, Pedro;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Long, Sarah S;
Poehling, Katherine A;
Cohen, Adam L.
his report compiles and summarizes all published recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults aged ≥19 years in the United States. This report also includes updated and new clinical guidance for implementation from CDC.
Bef...
Most of the influenza vaccines currently approved and available in the United States are produced by the propagation of influenza viruses in eggs (1-7). These vaccines therefore can contain small quantities of egg proteins. As of the 2022-23 influenza season, ACIP has recommended annual influenza vacci...
Woodworth, Kate R;
Moulia, Danielle;
Collins, Jennifer P;
Hadler, Stephen C;
Jones, Jefferson M;
Reddy, Sujan C;
Chamberland, Mary;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Bell, Beth P;
Daley, Matthew F;
Mbaeyi, Sarah;
Dooling, Kathleen;
Oliver, Sara E.
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...
Estimated rates of influenza-associated hospitalization and death are generally highest among individuals 65 years of age and older (1-4), an age group for whom influenza vaccine effectiveness is often lower relative to younger populations (5, 6). Two inactivated influenza vaccines approved in the U.S. f...
Wallace, Megan;
Moulia, Danielle;
Blain, Amy E;
Ricketts, Erin K;
Minhaj, Faisal S;
Link-Gelles, Ruth;
Curran, Kathryn G;
Hadler, Stephen C;
!Asif, Amimah;
Godfrey, Monica;
Hall, Elisha;
Fiore, Anthony;
Meyer, Sarah;
Su, John R;
Weintraub, Eric;
Oster, Matthew E;
Shimabukuro, Tom T;
Campos-Outcalt, Doug;
Morgan, Rebecca L;
Bell, Beth P;
Brooks, Oliver;
Talbot, H. Keipp;
Lee, Grace M;
Daley, Matthew F;
Oliver, Sara E.
The mRNA-1273 (Moderna) COVID-19 vaccine is a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. During December 2020, the vaccine was granted Emergency Use Authorization (EUA) by the Food a...
Oliver, Sara E;
Wallace, Megan;
See, Isaac;
Mbaeyi, Sarah;
Godfrey, Monica;
Hadler, Stephen C;
Jatlaoui, Tara C;
Twentyman, Evelyn;
Hughes, Michelle M;
Rao, Agam K;
Fiore, Anthony;
Su, John R;
Broder, Karen R;
Shimabukuro, Tom;
Lale, Allison;
Shay, David K;
Markowitz, Lauri E;
Wharton, Melinda;
Bell, Beth P;
Brooks, Oliver;
McNally, Veronica;
Lee, Grace M;
Talbot, H. Keipp;
Daley, Matthew F.
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (A...
In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba®, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., Philadelphia, Pennsylvania]) as a 3-dose series. The FDA licensed a second MenB vaccine (MenB-4C [Bexsero®...